Pharmaceutical - AstraZeneca, Sanofi

Filter

Current filters:

AstraZenecaSanofi

Popular Filters

BIO-Europe 2013: Nanotechnology innovation and the pharma industry

BIO-Europe 2013: Nanotechnology innovation and the pharma industry

20-11-2013

The future of nanotechnology in pharma has been discussed by the Nanomedicine panel at the BIO-Europe…

AstraZenecaEuropePharmaceuticalResearchSanofi

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

News briefs: AstraZeneca suspends share repurchasing; New CMO for Sanofi; Research facility for Octapharma

02-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) saw its shares dip 1.8% to £29.02 in early afternoon…

AstraZenecaFinancialManagementOctapharmaPharmaceuticalResearchSanofi

Amylin said to be attracting several Big Pharma suitors

16-05-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Xarelto and Brilinta already well represented in US hospital formularies

03-04-2012

In the USA, formulary inclusion of the new anticoagulant Xarelto (rivaroxaban) from German drug major…

AstraZenecaBayerBrilintaBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingNorth AmericaotamixabanPfizerPharmaceuticalSanofiXarelto

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015

22-11-2011

The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million…

Asia-PacificAstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalPlavixSanofi

EU Pharma re-rating stalled against EU market vis-a-vis defensives, says Nomura analyst

13-11-2011

While European Union Pharma has outperformed the EU market by 16% year-to-date, the corresponding performance…

AstraZenecaEuropeFinancialGlaxoSmithKlinePharmaceuticalSanofi

AstraZeneca’s Brilinta shows mortality benefit over gold-standard Plavix

30-08-2011

There was good news for Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday, when the firm revealed…

AstraZenecaBrilintaCardio-vascularPharmaceuticalPlavixResearchSanofi

Back to top